Vivos Therapeutics (VVOS) Non-Current Assets (2019 - 2026)

Vivos Therapeutics (VVOS) has 8 years of Non-Current Assets data on file, last reported at $20.2 million in Q1 2026.

• On a quarterly basis, Non-Current Assets rose 163.5% year-over-year to $20.2 million in Q1 2026; TTM through Mar 2026 was $80.2 million, a 155.07% increase from a year earlier, with the FY2025 full-year figure at $20.8 million, up 165.88% from the prior year.
• Non-Current Assets for Q1 2026 stood at $20.2 million, down from $20.8 million in the prior quarter.
• Over the last five years, Non-Current Assets for VVOS reached as high as $20.8 million in Q4 2025 and fell as low as $7.7 million in Q1 2025.
• Historically, Non-Current Assets has averaged $11.0 million across 5 years, with a median of $8.3 million in 2023.
• On a YoY basis, Non-Current Assets climbed as much as 165.88% in 2025 and fell as far as 6.32% in 2025.
• Year by year, Non-Current Assets stood at $8.3 million in 2022, then decreased by 0.33% to $8.3 million in 2023, then retreated by 5.54% to $7.8 million in 2024, then soared by 165.88% to $20.8 million in 2025, then slipped by 2.62% to $20.2 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $20.2 million in Q1 2026, $20.8 million in Q4 2025, and $19.9 million in Q3 2025.